KING OF PRUSSIA, PA — SEED Therapeutics has advanced its experimental cancer treatment into a third dosing cohort in a first-in-human clinical trial, establishing early evidence that the drug degrades its intended protein target as the biotechnology company competes for a national industry award.
The oral treatment, ST-01156, is being evaluated in patients with advanced solid tumors. SEED reported that the drug degraded the RBM39 protein in patients’ blood cells, demonstrating that its proposed mechanism functions in humans.
The company reported no dose-limiting toxicities and described early safety and pharmacokinetic findings as encouraging. ST-01156 is also designed to penetrate the brain.
SEED develops molecular glue degraders, treatments intended to eliminate disease-associated proteins by directing the body’s cellular machinery to break them down.
The company is also developing additional drug candidates for cancer, neurodegenerative diseases and immune disorders, including a wholly owned therapy targeting the Tau protein and a second oncology program.
“Over the past year, we advanced ST-01156 from IND clearance to an active Phase 1 study and established early clinical proof of mechanism through RBM39 degradation in patients,” Chief Executive Officer Lan Huang stated.
SEED was nominated for the Prix Galien USA “Best Start-Up” Award for the second consecutive year. The award recognizes companies developing potential treatments for significant unmet medical needs.
The 2026 awards ceremony is scheduled for October 29 at the American Museum of Natural History in New York City.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.